A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
An open study to evaluate the safety of apatinib mesylate (YN968D1) 1,000mg monotherapy in
patients with unresectable locally advanced or metastatic Gastric cancer failed to standard
therapy.